Understanding inhibitor development in haemophilia A: Towards clinical prediction and prevention strategies

Haemophilia

Volumn 16, Issue SUPPL. 1, 2010, Pages 13-19

  Coppola, A ^a   Santoro, C ^b   Tagliaferri, A ^c   Franchini, M ^d   Di Minno, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Regional Reference Centre for Inherited Bleeding Disorders   (Italy)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Haemophilia; Inhibitor; Initial treatment; Prophylaxis; Risk factors; Risk stratification

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ANTIBODY TITER; ARTICLE; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR;

BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEMOPHILIA A; HUMANS; MUTATION; RISK FACTORS;

EID: 73949110642     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02175.x     Document Type: Article

References (37)

1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A. A systematic review. Haemophilia 2003, 9:418-435.
2. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008, 14(Suppl. 3):10-18.
3. Mehta R, Parameswaran R, Shapiro AD. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia 2006, 12(Suppl. 6):54-61.
4. Rodriguez-Merchan EC, Hedner U, Heijnen L. Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors? Haemophilia 2008, 14(Suppl. 6):68-81.
5. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004, 2:1047-1054.
6. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003, 102:2358-2363.
7. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006, 12:154-162.
8. White GC, Kempton CL, Grimsley A, Nielsen B, Roberts HR. Cellular immune responses in haemophilia: why do inhibitors develop in some, but not all haemophiliacs? J Thromb Haemost 2005, 3:1676-1681.
9. Astermark J, Lacroix-Desmazes S, Reding MT. Inhibitor development. Haemophilia 2008, 14(Suppl. 3):36-42.
10. ter Avest P, Fischer K, Mancuso ME. Risk stratification for inhibitor development at first treatment for severe haemophilia A patients: a tool for clinical practice. J Thromb Haemost 2008, 6:2048-2054.
11. Peerlinck K, Hermans C. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia 2006, 12:579-590.
12. Schwaab R, Brackmann HH, Meyer C. Haemophilia A: mutation type determines the risk of inhibitor formation. Thromb Haemost 1995, 74:1402-1406.
13. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factor VIII and IX. Haemophilia 2006, 12(Suppl. 6):15-22.
14. Margaglione M, Castaman G, Morfini M. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica 2008, 93:722-728.
15. Oldenburg J, Albert T, Schröder J, Aburubaiha Z, Müller-Reible C, Schwaab R. Classification of factor VIII gene mutations according to risk of inhibitor formation. Haemophilia 2008, 14(Suppl. 2):58.
16. Boekhorst J, Lari GR, d'Oiron R. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. Haemophilia 2008, 14:729-735.
17. Astermark J, Berntorp E, White GC, Kroner BL. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001, 7:267-272.
18. Astermark J, Oldenburg J, Escobar M, White GC, Berntorp E. Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005, 90:924-931.
19. Viel KR, Ameri A, Abshire TC. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009, 360:1618-1627.
20. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006, 107:3167-3172.
21. Astermark J, Oldenburg J, Carlson J. Polymorphisms in the TNFA gene and risk of inhibitor development in patients with hemophilia A. Blood 2006, 108:3739-3745.
22. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007, 5:263-265.
23. Matzinger P. The danger model: a renewed sense of self. Science 2002, 8:76-82.
24. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007, 109:4648-4654.
25. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multi-center cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007, 5:1383-1390.
26. Santagostino E, Mancuso ME, Rocino A. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005, 130:422-427.
27. Gouw SC, van der Bom JG, Auerswald G, Ettingshausen CE, Tedgård U, van der Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007, 109:4693-4697.
28. Goudemand J, Rothschild C, Demiguel V. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006, 107:46-51.
29. Chalmers EA, Brown SA, Keeling D. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007, 13:149-155.
30. Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with haemophilia. Thromb Haemost 2009, 101:674-681.
31. Lusher J, Abildgaard C, Arkin S. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost 2004, 2:574-583.
32. Bray GL, Gomperts ED, Courter S. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994, 83:2428-2435.
33. Rothschild C, Gill J, Scharrer I, Bray G. Transient inhibitors in the Recombinate PUP study. Thromb Haemost 2000, 84:145-146.
34. Goodeve AC, Williams I, Bray GL, Peake IR. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thromb Haemost 2000, 83:844-848.
35. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003, 9:38-49.
36. Kreuz W, Gill JC, Rothschild C. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005, 93:457-467.
37. Oldenburg J, Ivaskevicius V, Schröder J, Müller CR, Ganguly A. Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII. Thromb Haemost 2006, 95:903-905.